CN112533944A - 多特异性结合蛋白及其改进 - Google Patents

多特异性结合蛋白及其改进 Download PDF

Info

Publication number
CN112533944A
CN112533944A CN201980049197.9A CN201980049197A CN112533944A CN 112533944 A CN112533944 A CN 112533944A CN 201980049197 A CN201980049197 A CN 201980049197A CN 112533944 A CN112533944 A CN 112533944A
Authority
CN
China
Prior art keywords
seq
chain variable
amino acid
acid sequence
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980049197.9A
Other languages
English (en)
Chinese (zh)
Inventor
格雷戈里·P·常
安·F·张
杜金燕
丹尼尔·法伦
阿斯亚·格林贝格
威廉·哈尼
斯蒂芬·奥尼尔
罗尼·魏
布拉德利·M·伦德
比昂卡·普林茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragonfly Therapy Co ltd
Original Assignee
Dragonfly Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapy Co ltd filed Critical Dragonfly Therapy Co ltd
Priority to CN202311768455.3A priority Critical patent/CN117964773A/zh
Publication of CN112533944A publication Critical patent/CN112533944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980049197.9A 2018-05-28 2019-05-28 多特异性结合蛋白及其改进 Pending CN112533944A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311768455.3A CN117964773A (zh) 2018-05-28 2019-05-28 多特异性结合蛋白及其改进

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677137P 2018-05-28 2018-05-28
US62/677,137 2018-05-28
PCT/US2019/034186 WO2019231920A1 (en) 2018-05-28 2019-05-28 Multi-specific binding proteins and improvements thereon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311768455.3A Division CN117964773A (zh) 2018-05-28 2019-05-28 多特异性结合蛋白及其改进

Publications (1)

Publication Number Publication Date
CN112533944A true CN112533944A (zh) 2021-03-19

Family

ID=68697331

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980049197.9A Pending CN112533944A (zh) 2018-05-28 2019-05-28 多特异性结合蛋白及其改进
CN202311768455.3A Pending CN117964773A (zh) 2018-05-28 2019-05-28 多特异性结合蛋白及其改进

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311768455.3A Pending CN117964773A (zh) 2018-05-28 2019-05-28 多特异性结合蛋白及其改进

Country Status (15)

Country Link
US (1) US20210214436A1 (cg-RX-API-DMAC7.html)
EP (2) EP3802581A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021525731A (cg-RX-API-DMAC7.html)
KR (1) KR20210013160A (cg-RX-API-DMAC7.html)
CN (2) CN112533944A (cg-RX-API-DMAC7.html)
AU (1) AU2019277138B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020024235A2 (cg-RX-API-DMAC7.html)
CA (1) CA3101604A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003071A1 (cg-RX-API-DMAC7.html)
EA (2) EA202091977A1 (cg-RX-API-DMAC7.html)
IL (1) IL278943A (cg-RX-API-DMAC7.html)
MX (1) MX2020012905A (cg-RX-API-DMAC7.html)
PE (1) PE20210167A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011763YA (cg-RX-API-DMAC7.html)
WO (1) WO2019231920A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247255A1 (zh) * 2024-05-28 2025-12-04 映恩生物科技(上海)有限公司 一种抗dll3抗体、抗体药物偶联物及其应用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016230828B2 (en) * 2015-03-10 2020-10-22 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) * 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2020033702A1 (en) * 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
LT4279082T (lt) * 2019-01-17 2026-05-11 Immunocore Limited Farmacinės kompozicijos
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20230242647A1 (en) * 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业(上海)股份有限公司 一种抗pdl1×egfr的双特异性抗体
EP4225792A1 (en) * 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
TWI825544B (zh) * 2020-12-31 2023-12-11 大陸商信達生物製藥(蘇州)有限公司 含異二聚體抗體Fc的蛋白以及其製備方法
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
AU2022246607A1 (en) * 2021-03-31 2023-11-16 Janssen Biotech, Inc. Materials and methods for immune effector cells redirection
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118475601A (zh) * 2022-01-05 2024-08-09 苏州系统医学研究所 一种t细胞受体及其制备方法和用途
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
KR20260051102A (ko) * 2023-07-07 2026-04-15 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Egfr/c-met 이중특이적 결합 단백질 및 이의 용도
AU2024334818A1 (en) * 2023-08-30 2026-03-19 Mink Therapeutics, Inc. Novel t cell receptors that bind to preferentially expressed antigen in melanoma (prame) and methods of use thereof
WO2025233431A1 (en) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244416A1 (en) * 2001-11-12 2005-11-03 Gundram Jung Bispecific antibody molecule
CN104955953A (zh) * 2012-11-27 2015-09-30 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对,其制备方法及用途
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
US20170368169A1 (en) * 2016-03-21 2017-12-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN111065649A (zh) * 2017-08-16 2020-04-24 蜻蜓疗法股份有限公司 结合nkg2d、cd16和egfr、hla-e、ccr4或pd-l1的蛋白质

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809669A2 (en) * 2004-10-01 2007-07-25 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
US9562110B2 (en) * 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
WO2016087416A1 (en) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
EP3095792A1 (en) * 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
AU2018219348A1 (en) * 2017-02-10 2019-08-29 Dragonfly Therapeutics, Inc. Proteins binding BCMA, NKG2D and CD16
EP4273258A3 (en) * 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
AU2018220734B2 (en) * 2017-02-20 2025-03-06 Dragonfly Therapeutics, Inc. Proteins binding CD33, NKG2D and CD16
RU2021110369A (ru) * 2017-09-07 2021-06-01 Драгонфлай Терапьютикс, Инк. Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
CN112119093A (zh) * 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EA202091976A1 (ru) * 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на cd33, и их применение

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244416A1 (en) * 2001-11-12 2005-11-03 Gundram Jung Bispecific antibody molecule
CN104955953A (zh) * 2012-11-27 2015-09-30 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对,其制备方法及用途
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
US20170368169A1 (en) * 2016-03-21 2017-12-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN111065649A (zh) * 2017-08-16 2020-04-24 蜻蜓疗法股份有限公司 结合nkg2d、cd16和egfr、hla-e、ccr4或pd-l1的蛋白质

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247255A1 (zh) * 2024-05-28 2025-12-04 映恩生物科技(上海)有限公司 一种抗dll3抗体、抗体药物偶联物及其应用

Also Published As

Publication number Publication date
US20210214436A1 (en) 2021-07-15
EP4537904A3 (en) 2025-07-16
JP7726967B2 (ja) 2025-08-20
BR112020024235A2 (pt) 2021-05-04
SG11202011763YA (en) 2020-12-30
EP3802581A4 (en) 2022-04-13
PE20210167A1 (es) 2021-01-28
EA202091977A1 (ru) 2021-02-09
CL2020003071A1 (es) 2021-05-24
CN117964773A (zh) 2024-05-03
EP3802581A1 (en) 2021-04-14
KR20210013160A (ko) 2021-02-03
AU2019277138A1 (en) 2020-12-17
WO2019231920A1 (en) 2019-12-05
AU2019277138B2 (en) 2024-06-13
MX2020012905A (es) 2021-05-27
IL278943A (en) 2021-01-31
EA202092907A1 (ru) 2021-04-13
JP2021525731A (ja) 2021-09-27
JP2024023438A (ja) 2024-02-21
EP4537904A2 (en) 2025-04-16
CA3101604A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
JP7726967B2 (ja) 多重特異性結合タンパク質及びその改善
ES2954851T3 (es) Proteínas de unión multiespecífica que se unen a HER2, NKG2D y CD16, y métodos de uso
ES2986967T3 (es) Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
CN110662555B (zh) 靶向cea的多特异性结合蛋白
AU2018220734B2 (en) Proteins binding CD33, NKG2D and CD16
AU2021201451A1 (en) Proteins binding NKG2D, CD16, and EGFR, CCR4, or PD-L1
CN111432832A (zh) 结合nkg2d、cd16和c-型凝集素样分子-1(cll-1)的蛋白质
KR20240078657A (ko) Bcma, nkg2d 및 cd16에 결합하는 단백질
CN119735693A (zh) 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN111278460A (zh) 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN111278455A (zh) 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN111315778A (zh) 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN111132698A (zh) 结合nkg2d、cd16以及flt3的蛋白质
CN110891976A (zh) 结合gd2、nkg2d和cd16的蛋白质
WO2018148610A1 (en) Proteins binding psma, nkg2d and cd16
CN112437672A (zh) 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
WO2018152547A1 (en) Proteins binding cd123, nkg2d and cd16
RU2816716C2 (ru) Белки, связывающие NKG2D, CD16 и опухолеассоциированный антиген
RU2820603C2 (ru) Белки, связывающие cd33, nkg2d и cd16
RU2788531C2 (ru) Белок, связывающийся с nkg2d, cd16 и с опухолеспецифическим антигеном
EA046081B1 (ru) Мультиспецифические связывающие белки и их усовершенствования

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210319